Voloridge Investment Management
ONCE

Voloridge Investment Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Voloridge Investment Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,364
Closed -$1.64M – 651
2017
Q3 		$1.64M Buy
+18,364
New +$1.39M 0.04% 291
2016
Q3 		– Sell
-97,654
Closed -$4.99M – 370
2016
Q2 		$4.99M Buy
+97,654
New +$4.17M 0.14% 142

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Voloridge Investment Management's ONCE Position: Q4 2017 in Review

Voloridge Investment Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2017, closing a stake of 18,364 shares — an estimated $1.64M sold.

Voloridge Investment Management first reported a position in ONCE in Q2 2016 and held it in 2 quarters. The position peaked at $4.99M in Q2 2016. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

  • Voloridge Investment Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Voloridge Investment Management sold 18,364 Spark Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $1.64M.
  • Voloridge Investment Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2016 and held it in 2 quarters.
  • Voloridge Investment Management's Spark Therapeutics, Inc. Common Stock position peaked at $4.99M in Q2 2016.
  • 160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Voloridge Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.